These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12470255)

  • 1. Applications of SHAPES screening in drug discovery.
    Lepre CA; Peng J; Fejzo J; Abdul-Manan N; Pocas J; Jacobs M; Xie X; Moore JM
    Comb Chem High Throughput Screen; 2002 Dec; 5(8):583-90. PubMed ID: 12470255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design.
    Moore J; Abdul-Manan N; Fejzo J; Jacobs M; Lepre C; Peng J; Xie X
    J Synchrotron Radiat; 2004 Jan; 11(Pt 1):97-100. PubMed ID: 14646145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of NMR and high-throughput screening.
    Hajduk PJ; Burns DJ
    Comb Chem High Throughput Screen; 2002 Dec; 5(8):613-21. PubMed ID: 12470258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery.
    Fejzo J; Lepre CA; Peng JW; Bemis GW; Ajay ; Murcko MA; Moore JM
    Chem Biol; 1999 Oct; 6(10):755-69. PubMed ID: 10508679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of NMR screening in drug discovery.
    Fejzo J; Lepre C; Xie X
    Curr Top Med Chem; 2003; 3(1):81-97. PubMed ID: 12570779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synergy between combinatorial chemistry and high-throughput screening.
    Diller DJ
    Curr Opin Drug Discov Devel; 2008 May; 11(3):346-55. PubMed ID: 18428088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists.
    Wu B; Barile E; De SK; Wei J; Purves A; Pellecchia M
    Curr Top Med Chem; 2015; 15(20):2032-42. PubMed ID: 25986689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.
    Cancilla MT; He MM; Viswanathan N; Simmons RL; Taylor M; Fung AD; Cao K; Erlanson DA
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3978-81. PubMed ID: 18579375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of NMR in lead optimization: fragment-based approaches.
    Huth JR; Sun C
    Comb Chem High Throughput Screen; 2002 Dec; 5(8):631-43. PubMed ID: 12470260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR-based structural characterization of large protein-ligand interactions.
    Pellecchia M; Meininger D; Dong Q; Chang E; Jack R; Sem DS
    J Biomol NMR; 2002 Feb; 22(2):165-73. PubMed ID: 11883777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR and in silico screening.
    Rüdisser S; Jahnke W
    Comb Chem High Throughput Screen; 2002 Dec; 5(8):591-603. PubMed ID: 12470256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent development and application of virtual screening in drug discovery: an overview.
    Hou T; Xu X
    Curr Pharm Des; 2004; 10(9):1011-33. PubMed ID: 15078130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview on the current status on virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part II.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(6):1337-1358. PubMed ID: 28039691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMR in structure-based drug design.
    Carneiro MG; Ab E; Theisgen S; Siegal G
    Essays Biochem; 2017 Nov; 61(5):485-493. PubMed ID: 29118095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability.
    Dalvit C; Fogliatto G; Stewart A; Veronesi M; Stockman B
    J Biomol NMR; 2001 Dec; 21(4):349-59. PubMed ID: 11824754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective.
    Rester U
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):559-68. PubMed ID: 18600572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery.
    Hanzawa H; Shimada T; Takahashi M; Takahashi H
    J Biomol NMR; 2020 Nov; 74(10-11):501-508. PubMed ID: 32306215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.